<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219781">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222807</url>
  </required_header>
  <id_info>
    <org_study_id>0306110</org_study_id>
    <nct_id>NCT00222807</nct_id>
  </id_info>
  <brief_title>Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus</brief_title>
  <official_title>Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Association for Geriatric Psychiatry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes
      mellitus in patients with schizophrenia. As part of the study, we collect
      neuroendocrine-immune data on patients with first episode, treatment naive psychosis,
      patients with newly diagnosed schizophrenia and normal healthy controls.

      Regardless the treatment status, we collect the same neuroendocrine-immune data on the
      participants after 2 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes
      mellitus in patients with schizophrenia. As part of the study, we collect
      neuroendocrine-immune data on patients with first episode, treatment naive psychosis,
      patients with newly diagnosed schizophrenia and normal healthy controls.

      Regardless the treatment status, we collect the same neuroendocrine-immune on the
      participants (patients and controls) after 2 months. Thus, our study does not control
      treatment. Patients take treatment in consultation with their physician. Some of them even
      decide not to take any medications. At the 2nd visit, we do ask them about the the
      medications they are taking if any.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2003</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Delusional Disorder</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples are collected, stored at minus 70 degree C and analyzed in batches.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with psychosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association

        Exclusion Criteria:

          -  Diabetes, type 1 or 2

          -  Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance
             use)

          -  Age above 50 or age below 14
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ripu D Jindal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ripu D Jindal, MD</last_name>
    <phone>412 512 9516</phone>
    <email>jindalr@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard S Guido, MD</last_name>
      <phone>412-383-1480</phone>
      <email>guidrs@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ripu D Jindal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matcheri S Keshavan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Eklund, BSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia A Thomas, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 16, 2011</lastchanged_date>
  <firstreceived_date>September 13, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Ripu Jindal, MD Clinical Assistant Professor</name_title>
    <organization>University of Pittsburgh</organization>
  </responsible_party>
  <keyword>schizophrenia, psychosis, type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Schizophrenia, Paranoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
